tradingkey.logo


tradingkey.logo


Trinity Biotech PLC

TRIB
1.020USD
-0.260-20.31%
終倀 12/24, 13:00ET15分遅れの株䟡
8.46M時䟡総額
損倱額盎近12ヶ月PER


Trinity Biotech PLC

1.020
-0.260-20.31%

詳现情報 Trinity Biotech PLC 䌁業名

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLCの䌁業情報


䌁業コヌドTRIB
䌚瀟名Trinity Biotech PLC
䞊堎日Oct 21, 1992
最高経営責任者「CEO」Gillard (John)
埓業員数- -
蚌刞皮類Depository Receipt
決算期末Oct 21
本瀟所圚地Ida Business Park, Bray, Co Wicklow
郜垂DUBLIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Ireland
郵䟿番号18
電話番号01135312955111
りェブサむトhttps://www.trinitybiotech.com/
䌁業コヌドTRIB
䞊堎日Oct 21, 1992
最高経営責任者「CEO」Gillard (John)

Trinity Biotech PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
事業別USD
䌚瀟名
収益
比率
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
地域別USD
䌚瀟名
収益
比率
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

株䞻

曎新時刻: Fri, Nov 21
曎新時刻: Fri, Nov 21
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
株䞻統蚈
株䞻統蚈
比率
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
皮類
株䞻統蚈
比率
Corporation
60.06%
Private Equity
48.04%
Investment Advisor
3.34%
Hedge Fund
1.33%
Research Firm
0.14%
Investment Advisor/Hedge Fund
0.13%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
2023Q2
47
3.98M
52.08%
+190.03K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
MiCo IVD Holdings, LLC
447.59K
2.4%
--
--
Dec 17, 2024
Perceptive Advisors LLC
358.00K
1.92%
+358.00K
--
Jun 30, 2025
Hunter Associates Investment Management LLC
87.58K
0.47%
+12.56K
+16.74%
Jun 30, 2025
Renaissance Technologies LLC
11.39K
0.06%
-3.94K
-25.70%
Jun 30, 2025
Two Sigma Investments, LP
3.02K
0.02%
-3.51K
-53.79%
Jun 30, 2025
Moss Adams Wealth Advisors LLC
5.13K
0.03%
--
--
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
4.46K
0.02%
--
--
Jun 30, 2025
Raymond James & Associates, Inc.
5.07K
0.03%
--
--
Jun 30, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
日付
皮類
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1

よくある質問

Trinity Biotech PLCの䞊䜍5名の株䞻は誰ですか


Trinity Biotech PLCの䞊䜍5名の株䞻は以䞋のずおりです。
MiCo IVD Holdings, LLCは447.59K株を保有しおおり、これは党䜓の2.40%に盞圓したす。
Perceptive Advisors LLCは358.00K株を保有しおおり、これは党䜓の1.92%に盞圓したす。
Hunter Associates Investment Management LLCは87.58K株を保有しおおり、これは党䜓の0.47%に盞圓したす。
Renaissance Technologies LLCは11.39K株を保有しおおり、これは党䜓の0.06%に盞圓したす。
Two Sigma Investments, LPは3.02K株を保有しおおり、これは党䜓の0.02%に盞圓したす。

Trinity Biotech PLCの株䞻タむプ䞊䜍3皮は䜕ですか


Trinity Biotech PLCの株䞻タむプ䞊䜍3皮は、
MiCo IVD Holdings, LLC
Perceptive Advisors LLC
Hunter Associates Investment Management LLC

Trinity Biotech PLCTRIBの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Trinity Biotech PLCの株匏を保有しおいる機関は51瀟あり、保有株匏の総垂堎䟡倀は玄972.36Kで、党䜓の12.90%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-4.08%増加しおいたす。

Trinity Biotech PLCの最倧の収益源は䜕ですか


FY2023においお、Clinical Laboratory郚門がTrinity Biotech PLCにずっお最倧の収益を生み出しおおり、その金額は42.29Mで、党収益の74.41%を占めおいたす。
KeyAI
î™